Pharmacokinetic Interactions Between Buprenorphine and Kaletra (Lopinavir/Ritonavir)
Status:
Completed
Trial end date:
2008-08-01
Target enrollment:
Participant gender:
Summary
The main purpose of this protocol is to study the effect of an HIV medication, Kaletra
(lopinavir/ritonavir), on buprenorphine in non-HIV infected people who have been receiving
the same dose of buprenorphine for at least 3 weeks.
Study Hypothesis:
Kaletra (lopinavir/ritonavir) will increase buprenorphine plasma levels without any
significant clinical effect on the subject or need for dose adjustment.